Turn real-world data into AI-ready assets that stay defensible.
You sit on clinical and claims data that could power AI, but it has to hold up to regulators and partners first. Integral assesses, engineers, and documents that data so it moves into AI pipelines with defensibility documentation attached.
The real-world data opportunity
Clinical trial data, claims records, and real-world evidence datasets are among the most valuable assets for AI training and evaluation. But they are also among the most sensitive. Every use requires a defensible determination that the data can move without re-identification risk.
Without that determination, data sits unused. With it, the same data powers drug discovery models, clinical decision support, population health analytics, and AI-driven research. Integral provides the determination and the documentation so the data can move.
What Integral delivers
Defensible by Expert Determination
A signed, scoped opinion from qualified statistical experts on re-identification risk. The highest standard of defensibility under HIPAA for clinical and claims data.
Signal preserved for research
Privacy engineering is tuned to preserve the analytical and research value of the data. Utility metrics document what is retained after remediation.
Control retained
You decide who gets access and under what terms. Integral is a privacy layer; it does not broker, resell, or intermediate your data relationships.
How it works
Align on scope and standards
Integral works with your team to understand the data, the intended AI use cases, downstream recipients, and the regulatory requirements.
Expert Determination
Qualified statistical experts assess re-identification risk for each dataset and intended use. The result is a signed, scoped determination with methodology provenance.
Privacy engineering
Signal-preserving remediation is applied and documented. Utility is measured before and after engineering so the tradeoff is explicit.
Deliver with documentation, then re-assess
Data ships with the full evidence package. As datasets, recipients, or use cases change, continuous re-assessment keeps the determination current.
Trusted by teams building on sensitive data
“Integral goes beyond the initial report. They peel back the layers and keep asking the right questions until they truly understand how your data works. That level of attention is what you need when pharma clients are asking hard questions and expect real answers.”
“Before Integral, compliance projects were a limiting factor. It would take months to get one done, and we still couldn't explain why certain decisions were made. Integral's approach is notably more creative and scalable than any other solution. Their operations process is very clean, which builds confidence with our clients. And by automating most of the process, Integral has cut our timelines in half. That speed has made a huge difference for us.”
“We wanted a solution that would allow us to massage the data sets we were already using and augment them over time - without requiring a from-scratch re-analysis of the overarching data set. Today, all our data sources go through Integral before they ever hit an environment we access. Without Integral's flexibility, we couldn't stay defensible as data shifts.”
Frequently asked questions
What types of pharma and life sciences data does Integral handle?
Clinical trial data, real-world evidence, claims records, electronic health records, genomic data, and other sensitive datasets used in research and AI development.
How is Expert Determination different from Safe Harbor?
Safe Harbor follows a fixed list of 18 identifiers to remove. Expert Determination is a statistical assessment of re-identification risk performed by qualified experts, scoped to the specific dataset and use case. It preserves more data utility while providing a higher standard of defensibility.
Does the data leave our environment?
It does not have to. Integral supports forward-deployed engagements in your infrastructure: cloud, VPC, on-prem, or air-gapped.
How do we handle multi-party data collaborations?
Each collaboration is scoped independently. The determination accounts for the specific recipients, uses, and regulatory context of each engagement.
